-+ 0.00%
-+ 0.00%
-+ 0.00%

Valion Bio Delays Third-Quarter Report to Finalize Financial Statements

PUBT·11/16/2026 21:08:03
Listen to the news
Valion Bio Delays Third-Quarter Report to Finalize Financial Statements
  • Valion Bio delayed its Form 10-Q for the quarter ended September 30, 2026.
  • It needs additional time to finalize financial statements and disclosures, with filing expected within the five-calendar-day extension.
  • Preliminary quarterly net loss is approximately $16.2 million, compared with $2.6 million a year earlier.
  • Estimated net loss for the nine months ended September 30, 2026, is approximately $29.5 million, versus $6 million in 2025.
  • The wider losses primarily reflect asset and goodwill impairments, higher operating expenses and interest expense.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-008846), on November 16, 2026, and is solely responsible for the information contained therein.